ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2016
Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Pathophysiological role and clinical applications of HER-2 expression in meningiomas: a systematic review.Annals of medicine and surgery (2012) · 2025Article
- Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.Journal of neuropathology and experimental neurology · 2025Article
- Cancer stem cells in meningiomas: novel insights and therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Expressions of Progesterone Receptor of Orbital Meningiomas in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2022Observational
- Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.Neuro-oncology · 2022Article
- NDRG2 inhibition facilitates angiogenesis of hepatocellular carcinoma.Open medicine (Warsaw, Poland) · 2021Article
- Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02.Translational oncology · 2020Article
- Recurrence/Regrowth in Grade I Meningioma: How to Predict?Frontiers in oncology · 2020Article
- Nervous NDRGs: the N-myc downstream-regulated gene family in the central and peripheral nervous system.Neurogenetics · 2019Review
- The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Prognostic value of ErbB2/HER2 in human meningiomas.PloS one · 2018Article
- RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are common, usually benign tumors of the central nervous system that have a high rate of post-surgical recurrence or regrowth. We determined expression of the proteins merlin, NDRG2, ERBB2, and c-MYC in meningiomas using immunohistochemistry and assessed relationships between protein expression and gender, age, tumor grade, and recurrence or regrowth. The study sample comprised 60 patients, (44 women and 16 men) with a mean age of 53.2 ± 12.7 years. Tumors were classified as grade I (n=48) or grades II and III (n=12). Expression of merlin, NDRG2, ERBB2, and c-MYC was not significantly different statistically with relation to gender, age, or meningioma recurrence or regrowth. Merlin was expressed in 100% of the cases. No statistically significant difference between tumor grade and recurrence or regrowth was identified. Statistically significant differences were identified between the mean age of patients with grade I (54.83 ± 11.60) and grades II and III (46.58 ± 15.08) meningiomas (P=0.043), between strong c-MYC expression and grades II and III (P<0.001), and between partial surgical resection and tumor recurrence or regrowth (P<0.001). These findings reveal the lower mean age among grades II and III meningioma patients than grade I patients, the influence of the protein merlin on tumorigenesis, the association of c-MYC with aggressive meningiomas, and that partial surgical resection is associated with tumor recurrence or regrowth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.